Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response

Objective: Sumatriptan is effective in the acute treatment of migraine, However, about 15% of patients with migraine do not experience headache relief after sumatriptan, and up to 40% may experience recurrence of headache within 24 hours. We studied whether pharmacokinetic or pharmacodynamic differences may explain these different clinical effects. Methods: We compared the pharmacokinetic profiles of-subcutaneous sumatriptan in 14 patients who consistently had headache relief without headache recurrence, in 12 patients who had headache recurrence in every attack, and in six patients who did not have headache relief after sumatriptan, Because the antimigraine action of sumatriptan may be mediated through vasoconstriction of cranial blood vessels, me also compared in thesepatients changes in blood vessel diameter and blood velocity in the common, internal, and external carotid arteries. Results: Despite sufficient power of the study, no important differences in pharmacokinetic and pharmacodynamic profiles between the three patient groups were detected. Conclusion: Headache recurrence and lack of headache relief after sumatriptan do not appear to be explained by pharmacokinetic or pharmacodynamic differences between patients, which may be an important finding for the development of novel antimigraine drugs.